This website uses cookies to among other things collect statistical information on the use of our website with the goal of improving user experience. For details please read the Cookie Policy. I ACCEPT Skip to main navigation ROYALTY PHARMA Transforming the Funding of Life Sciences Through Collaborative Capital IR HERO STATS 150 + YEARS OF EXPERIENCE $20bn + CAPITAL DEPLOYED 50 + ROYALTY ACQUISITIONS ENGAGE WITH US We work directly with innovators across the life sciences, including research institutions, inventors, and biopharma companies. LNK OUR APPROACH OUR APPROACH APPROVED PRODUCT ROYALTY MONETIZATION The biopharmaceutical industry is undergoing a period of strong growth and unprecedented innovation. We intend to further this innovation by acquiring royalties on leading biopharmaceutical products. LNK ROYALTY MONETIZATION READ MORE DEVELOPMENT CANDIDATES We seek to acquire royalties on innovative product candidates in the late-stages of clinical development. We collaborate directly with innovators to acquire a new synthetic royalty, monetize an existing royalty or provide capital to an innovator to co-fund clinical development of a product candidate in exchange for a royalty. LNK RD PARTNERSHIP READ MORE M&A We take a flexible approach to acquisitions. In biopharmaceutical acquisitions, the focus of an acquirer is typically on strategic assets over which the target has operational control, rather than on passive financial assets such as royalties. We can partner with strategic acquirers which buy companies that own both strategic assets and passive royalties. LNK MA READ MORE 110 E 59th Street FL 33 New York, NY 10022 +1 (212) 883-0200 CONTACT@ROYALTYPHARMA.COM SOCIAL ICONS LEGAL NAV TERMS PRIVACY © 2021 Royalty Pharma, RP Management LLC. All Rights Reserved.